Canada has taken a significant step towards increasing access to crucial medications with Health Canada's approval of a second generic version of semaglutide injections. This development positions Canada as the first country among the G7 nations to greenlight generic alternatives to the widely used brand-name drug, Ozempic. The approvals, granted on April 28 and May 1, 2026, to Dr. Reddy's Laboratories and Canadian-based Apotex respectively, are anticipated to drive down costs and enhance availability for Canadians grappling with type 2 diabetes and obesity.
Affordability and Accessibility Surge
The expiration of the patent for Novo Nordisk's Ozempic in Canada in early January 2026 opened the door for generic manufacturers. Health Canada's rigorous review process ensures that these generic versions are pharmaceutically equivalent to the brand-name drug, meeting all criteria for safety, efficacy, and quality. According to Health Canada, generic medications are typically 45 to 90 percent cheaper than their brand-name counterparts. This cost reduction is a crucial development for many Canadians who rely on semaglutide injections and face substantial out-of-pocket expenses monthly. Martin Arès, President of Apotex Canada and Rest of World, highlighted the company's commitment to improving access to medicines, stating, "This approval reflects our Canadian roots and our commitment to improving access to medicines. As a Canadian-based global pharmaceutical company, we are proud to bring forward a high-quality, affordable alternative that supports patients, prescribers, and the long-term sustainability of our healthcare system."
Expanding the Therapeutic Landscape
Semaglutide injections are primarily indicated for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels. However, the drug has also gained prominence for its effectiveness in aiding weight loss in obese patients, making it a sought-after treatment for a broader population. Health Canada's approval of generic versions means that more Canadians will likely have access to these beneficial treatments, potentially alleviating pressure on the healthcare system and improving patient outcomes. The department is actively reviewing seven additional submissions for generic semaglutides, indicating a commitment to further diversifying the market and ensuring a robust supply chain. These reviews are expected to lead to more regulatory decisions in the coming weeks and months, further expanding options for Canadians.
Ongoing Monitoring and Future Outlook
Health Canada emphasizes that it will continue to monitor the safety and effectiveness of all authorized generic semaglutide products, as it does with all medications. Should any unexpected safety or effectiveness concerns arise, the department is prepared to take appropriate action to protect public health. The availability of these generic options is expected to have a positive impact on Canada's healthcare system, not only through potential cost savings for patients but also by contributing to the long-term sustainability of drug procurement and supply. The move by Canada to be the first G7 nation to approve generic semaglutide underscores its proactive approach to pharmaceutical accessibility and innovation.